Floatz logo

RITONAVIR

Thrombocytopenia

City of Hope Medical CenterSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Thrombocytopenia cohort.

Asset / SponsorPhaseRating
Recombinant Human Thrombopoietin
Sun Yat-sen University
Phase 4BBB
sb-497115-gr
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
Avatrombopag
Second Affiliated Hospital of Guangzhou Medical University
Phase 4BB
FILGRASTIM
OHSU Knight Cancer Institute
Phase 2BB
Hetrombopag
Sun Yat-sen University
Phase 3BB

View all 50 →

Same molecule, other indications

RITONAVIR is also rated in:

chronic hepatitis C virus infectionDormant
BBB
Indicative ·
76 / 100
View asset →
hepatitis C virus infectionDormant
BBB
Indicative ·
76 / 100
View asset →
HIV infectious diseaseDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →